TY 2136
Alternative Names: TY-2136; TY-2136bLatest Information Update: 28 Oct 2024
At a glance
- Originator TYK Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Protein tyrosine kinase inhibitors; Proteolysis; ROS1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- No development reported Cancer; Non-small cell lung cancer
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Cancer in China (Parenteral)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in China (Parenteral)
- 20 Apr 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (PO) (NCT05769075)